Lymphoma Clinical Trial
Official title:
Improving Quality of Life in Hematologic Cancer Survivors by Closing the Exercise Intention—Behavior Gap: a Phase II Randomized Controlled Trial of a Theory-based, Telephone-delivered Exercise Counselling Intervention
This study evaluates the impact of a 12-week theory-based exercise telephone counselling program (versus a self-directed exercise group) on closing the exercise intention-behavior gap in a sample of hematologic cancer survivors.
Problem: Regular exercise participation improves quality of life and physical function for
cancer survivors. Unfortunately, the most effective way of promoting exercise to cancer
survivors has yet to be determined, and as a result, many survivors are inactive.
Theory-based efforts have typically focused on promoting intentions to exercise, though we
are now discovering that only about half of those who intend to exercise actually follow
through on their intentions. This is known as the exercise intention-behavior gap. It also
appears that survivors are more likely to follow-through on their intention to exercise when
they report employing key behavioral and motivational strategies (i.e., creating detailed
exercise plans, feeling capable and obligated to exercise, perceiving it to be beneficial and
fun, and avoiding the temptation to participate in alternative activities) which may be
promoted via telephone counselling.
Objective: To determine whether a theory-based telephone counselling intervention focused on
closing the exercise intention-behavior gap is feasible and can improve exercise levels,
motivation, quality of life, and fatigue in hematologic cancer survivors.
Methods: A two-armed randomized controlled trial will compare the efficacy of telephone
counselling versus a control condition (self-directed with Canada's Physical Activity Guide).
All participants will be asked to increase their exercise by at least 60 minutes per week.
Hematologic cancer survivors who previously participated in an exercise survey study and
indicated interest in participating in future exercise related research (N=407) will be
contacted to participate in the current trial. Eligible participants will be randomized in a
1:1 ratio to either the telephone counseling group or a self-directed exercise group.
Participants in the intervention arm will receive 12 weekly telephone counseling sessions
aimed at helping survivors follow-through on their exercise intention. A sample of
approximately N=66 hematologic cancer survivors will be recruited for this 12-week trial.
Data will be collected via online surveys assessing changes in exercise levels, motivation,
quality of life, and fatigue. Feasibility will be determined by eligibility percentage,
recruitment percentage, adherence rate, assessment completion rate, adverse events, and
ratings of program acceptability.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |